Summary Ongoing trials are evaluating the role of other targeted therapies in patients with advanced HCC.
正在进行的一些试验是评估其它靶向治疗对于进展期肝癌的病人的作用。
The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial.
目前还没有2期或3期试验对索拉非尼与多柔比星联用治疗晚期HCC患者进行评价。
For those patients with advanced HCC, who have had surgical resection, with the surgery impact the safety and efficacy of sorafenib?
对于已进行了手术的晚期肝癌患者，手术会影响索拉非尼的安全性和疗效吗？
Conclusions Palliative resection of liver cancer and implanted with a drug delivery system can improve survival duration and life quality of patients with advanced HCC.
结论癌肿姑息切除联合肝动脉置管埋泵化疗有助于提高中晚期肝癌患者的生存时间和生命质量。
I think recently we have become able in the past few years to split the "unresectable" HCC patients into two categories: those at intermediate stage and those at advanced stage.
我认为在过去的几年中，我们已能够将不能切除HCC患者分为两类：中期患者和晚期患者。
International Digest: Most HCC is not diagnosed until the disease is at an advanced stage. What novel molecular markers are there for the early diagnosis for HCC?
国际肝病：大多数肝癌在诊断时已是晚期。HCC早期诊断的新分子标志有哪些？
CONCLUSIONS: Characteristics that distinguish elderly from younger HCC patients include lower M/F ratio, worse performance status, lower rate of HCV infection, and less advanced underlying cirrhosis.
结论：年长组区别于年轻组HCC患者的特征包括较低的M/F比率、更差的体力状态、较低的HCV感染率以及较少进展的肝硬化。
CONCLUSIONS: Characteristics that distinguish elderly from younger HCC patients include lower M/F ratio, worse performance status, lower rate of HCV infection, and less advanced underlying cirrhosis.
结论：年长组区别于年轻组HCC患者的特征包括较低的M/F比率、更差的体力状态、较低的HCV感染率以及较少进展的肝硬化。
应用推荐